Debiopharm to acquire Affinium's antibiotic clinical assets and platform

11 February 2014

Swiss drug developer Debiopharm Group has entered into an agreement to acquire Canadian venture capital backed biotech firm Affinium Pharmaceuticals’ clinical and preclinical assets as well as its technology platform. Financial terms were not disclosed.

The clinical assets include AFN-1252, a FabI inhibitor designated by the US Food and Drug Administration as a Qualified Infectious Disease Product (QIDP) which has successfully completed a Phase IIa study for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and its prodrug AFN-1720, currently in Phase I clinical development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical